Related Experiment Video
Updated: Aug 3, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Pharmacophore based virtual screening for identification of effective inhibitors to combat HPV 16 E6 driven cervical
Anbuselvam Mohan1, Sneha Krishnamoorthy2, Rajalakshmi Sabanayagam2
1Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore, 641 021, Tamil Nadu, India; Department of Biotechnology, Selvamm Arts and Science College (Autonomous), Namakkal, 637003, Tamil Nadu, India.
Abstract:
Targeting HPV16 E6 has emerged as an effective drug target for the treatment/management of cervical cancer. We utilized pharmacophore-based virtual screening, molecular docking, absorption, distribution, metabolism and excretion (ADME) prediction, and molecular dynamics simulation approach for identifying potential inhibitors of HPV16 E6. Initially, we generated a ligand-based pharmacophore model based on the features of four known HPV16 E6 inhibitors (CA24, CA25, CA26, and CA27) via the PHASE module implanted in the Schrödinger suite. We constructed four-point pharmacophore features viz., three hydrogen bond acceptors (A) and one aromatic ring (R). The common pharmacophore feature further employed as a query for virtual screening against the ASINEX database via Schrödinger suite. The pharmacophore-based virtual screening filtered out top 2000 hits, based on the fitness score. We then applied the high throughput virtual screening (HTVS), standard precision (SP) and extra precision (XP). 1000 compounds were obtained from HTVS docking. Based on the glide score, they were further filtered to 500 hits by employing docking in standard precision mode. Finally, the best four hits and a negative molecule were identified using docking in XP mode. The four lead compounds and a negative molecule were then further subjected to ADME profile prediction by engaging Qikprop module. The ADME properties of the four lead molecules indicate good pharmacokinetic (PK) properties rather than the negative molecule. The binding stability of the HPV16 E6-hit complexes were investigated at a different time scale (100 ns) by using the desmond package and the results were examined using Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) and it revealed the stability of the protein-ligand complex throughout the simulation. Key residues, CYS 51 and GLN 107, also play a crucial role in enhancing the stability of the protein-ligand complex during the simulation. Furthermore, the binding free energy of the HPV16 E6-leads complexes was analyzed by prime which revealed that the ΔGbind coulomb and ΔGbind vdW interactions are crucially contributes to the binding affinity. In order to validate the computational findings, the efficacy of benzoimidazole and benzotriazole were ascertained for regulating ME180 cervical cancer cell survival, migration and ability to release MMP-2.
Insights
Researchers identified potential inhibitors for Human Papillomavirus type 16 E6 (HPV16 E6), a key target in cervical cancer treatment. Computational methods predicted compounds with favorable drug-like properties and stable binding, validated by experimental testing.
Area of Science:
- Computational drug discovery
- Oncology
- Virology
Background:
- Human Papillomavirus type 16 E6 (HPV16 E6) is a validated drug target for cervical cancer treatment.
- Developing novel inhibitors is crucial for effective cervical cancer management.
Purpose of the Study:
- To identify novel small molecules that inhibit HPV16 E6 using computational approaches.
- To predict pharmacokinetic properties and binding stability of potential inhibitors.
Main Methods:
- Pharmacophore-based virtual screening of the ASINEX database using Schrödinger suite.
- Molecular docking (HTVS, SP, XP) to identify lead compounds.
- ADME prediction using Qikprop and molecular dynamics simulations with Desmond.
- Binding free energy analysis using Prime and experimental validation.
Main Results:
- A four-point pharmacophore model (3 H-bond acceptors, 1 aromatic ring) was generated.
- Virtual screening identified four lead compounds with favorable ADME and PK properties.
- Molecular dynamics simulations confirmed stable binding of lead compounds to HPV16 E6.
- Experimental validation demonstrated the efficacy of identified compounds against cervical cancer cells.
Conclusions:
- Computational methods successfully identified potent inhibitors of HPV16 E6.
- The identified compounds show promise for cervical cancer therapy.
- Further development of these inhibitors could lead to new treatment strategies.
